Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease

被引:55
|
作者
Yoon, K-C
Jeong, I-Y
Im, S-K
Park, Y-G
Kim, H-J
Choi, J.
机构
[1] Chonnam Natl Univ Med Sch & Hosp, Dept Ophthalmol, Kwangju 501757, South Korea
[2] Chonnam Natl Univ Med Sch & Hosp, Dept Hematol Oncol, Kwangju 501757, South Korea
[3] Eun Hosp, Dept Obstet, Kwangju, South Korea
关键词
dry eye; graft-versus-host disease; umbilical cord serum eyedrops;
D O I
10.1038/sj.bmt.1705566
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal sensitivity test, tear film break up time (BUT), Schirmer test, tear clearance rate (TCR), and corneal fluorescein staining were performed before and 2 and 6 months after treatment. Six months after treatment, significant improvement was observed in symptom score (from 3.83 +/- 0.38 to 0.83 +/- 0.57, P < 0.01), corneal sensitivity (from 52.08 +/- 6.06 mm to 57.50 +/- 3.00 mm, P < 0.01), tear film BUT (from 2.50 +/- 0.91 s to 5.71 +/- 1.04 s, P < 0.01), and keratoepitheliopathy score (from 7.42 +/- 2.02 to 1.29 +/- 0.46, P < 0.01). There was no significant change in Schirmer test and TCR results. No significant complications associated with the use of the eyedrops were observed. Umbilical cord serum eyedrops are safe and may be an effective way to treat severe dry eye associated with GVHD.
引用
收藏
页码:231 / 235
页数:5
相关论文
共 50 条
  • [31] Boston Scleral Lens Prosthetic Device for treatment of severe dry eye in chronic graft-versus-host disease
    Jacobs, Deborah S.
    Rosenthal, Perry
    CORNEA, 2007, 26 (10) : 1195 - 1199
  • [32] Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease Associated With Ocular Graft-Versus-Host Disease
    Wong, Calvin W.
    Le, Harrison L.
    Gombos, Dan S.
    Yee, Richard W.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [33] THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE
    VOGELSANG, GB
    HESS, AD
    SANTOS, GW
    BONE MARROW TRANSPLANTATION, 1988, 3 (05) : 393 - 398
  • [34] Dry eye disease and risk factors for corneal complications in chronic ocular graft-versus-host disease
    Kate, Anahita
    Singh, Swati
    Das, Anthony Vipin
    Basu, Sayan
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (04) : 1538 - 1544
  • [35] Ruxolitinib for treatment of Graft-versus-Host Disease
    Krueger, W. H.
    Neumann, T.
    Weigel, M.
    Plis, A.
    Schneidewind, L.
    Vaizian, R.
    Schmidt, C. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 70 - 71
  • [36] Treatment options for graft-versus-host disease
    Hilgendorf, Inken
    Wolff, Daniel
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (09): : 731 - 743
  • [37] Advances in the treatment of graft-versus-host disease
    Vogelsang, GB
    LEUKEMIA, 2000, 14 (03) : 509 - 510
  • [38] THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE
    HENEY, D
    BAILEY, CC
    LEWIS, IJ
    BIOMEDICINE & PHARMACOTHERAPY, 1990, 44 (04) : 199 - 204
  • [39] The Treatment of Chronic Graft-Versus-Host Disease
    Wolff, Daniel
    Bertz, Hartmut
    Greinix, Hildegard
    Lawitschka, Anita
    Halter, Joerg
    Holler, Ernst
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (43): : 732 - I
  • [40] Pathophysiology and treatment of graft-versus-host disease
    Flowers, MED
    Kansu, E
    Sullivan, KM
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (05) : 1091 - +